BioCentury
ARTICLE | Clinical News

China FDA approves IND for Canbridge's GBM candidate

April 13, 2018 3:18 PM UTC

Canbridge Life Sciences Ltd. (Beijing, China) said China FDA approved an IND to begin a Phase II/III trial of asunercept (APG101, CAN-008) to treat glioblastoma multiforme (GBM).

A spokesperson told BioCentury that Canbridge plans to dose the first patient in the trial later this year...

BCIQ Target Profiles

Fas receptor (CD95)